Skip to main
OABI
OABI logo

OmniAb Inc (OABI) Stock Forecast & Price Target

OmniAb Inc (OABI) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OmniAb Inc demonstrated strong financial performance in 1Q25, reporting revenues of $4.2 million, which reflects a 9% increase year-over-year, highlighting the company's ability to grow amid a competitive landscape. The company also showed progress in reducing net losses to $18.2 million, or ($0.17) per share, compared to a loss of $19.0 million, or ($0.19) per share in the prior year, indicating improved operational efficiency. With a solid balance sheet and anticipated catalysts in both near- and long-term R&D efforts, OmniAb is well-positioned for upward momentum in its stock performance.

Bears say

OmniAb Inc. has experienced a decline in stock value post-merger with Avista Public Acquisition Corporation II, which mirrors adverse market trends impacting similar biotechnology transactions and established firms. The company's projected operating cash burn for the current year is expected to be below that of 2024, indicating potential concerns regarding financial sustainability and management of expenditures. These financial dynamics raise questions about the company's short-term viability and ability to maintain investor confidence in a challenging market environment.

OmniAb Inc (OABI) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OmniAb Inc (OABI) Forecast

Analysts have given OmniAb Inc (OABI) a Strong Buy based on their latest research and market trends.

According to 3 analysts, OmniAb Inc (OABI) has a Strong Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OmniAb Inc (OABI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.